Tetrahydrocannabiphorol

CB1 agonism produces dose-dependent tachycardia as a class effect. High-potency synthetic cannabinoids with CB1 affinity profiles comparable to THCP have been associated with cardiovascular emergencies including arrhythmia and myocardial infarction. Patients with unstable angina, recent MI, heart failure, or arrhythmia disorders face amplified risk from potent CB1 activation.

THCP's full CB1 agonism at an affinity comparable to synthetic cannabinoids (CP55940) places it in a risk category associated with acute psychotic episodes, hallucinations, and disorganized thinking. Cannabis-associated psychotic symptoms occur in ~0.47% of cannabis users lifetime, with substantially elevated risk in those with psychotic disorder history. THCP's ~33-fold higher CB1 affinity vs Δ9-THC predicts a lower threshold for psychotomimetic effects.

High-potency CB1 agonism is associated with mood destabilization in individuals with bipolar spectrum disorders. Full agonism at THCP's potency may lower the threshold for manic episode precipitation relative to THC.

Cannabis use disorder develops in ~9% of users overall and ~17% of adolescent-onset users. THCP's full agonism at CB1 predicts greater mesolimbic dopamine activation than THC's partial agonism, elevating reinforcement potential. Individuals with prior CUD face heightened relapse risk from exposure to a more potent CB1 agonist.

THCP is expected to undergo extensive hepatic CYP-mediated metabolism by analogy with Δ9-THC. Hepatic impairment reduces CYP enzyme capacity, potentially leading to elevated plasma THCP concentrations, prolonged effect duration, and increased risk of adverse effects including severe cognitive impairment and psychotomimetic symptoms.

Δ9-THC crosses the placenta and is present in breast milk. THCP's greater lipophilicity and higher CB1 potency predict at minimum equivalent fetal/neonatal exposure with potentially amplified pharmacological effects. Developmental consequences of exposing the immature endocannabinoid system to a full CB1 agonist are unknown.

High-potency cannabis use during adolescence is associated with poorer mental health outcomes including increased rates of anxiety, depression, and psychotic experiences (Hines et al. 2020). The endocannabinoid system plays a critical role in neurodevelopmental pruning of prefrontal circuits. THCP's exceptional CB1 potency and full agonism place it at the extreme end of the developmental risk spectrum for exogenous cannabinoids.

Δ9-THC inhibits CYP2C9 and CYP3A4 in vitro. THCP, metabolized by the same pathways by structural analogy, may act as both a CYP substrate and inhibitor. Co-administration with warfarin risks elevated INR and bleeding; with tacrolimus or cyclosporine risks nephrotoxicity; with clobazam risks excessive CNS depression.